Investors brace for Bayer court rulings after a $60 billion share price collapse.
Bayer shares have plunged by $60 billion as the market prices in downside risk from two imminent court rulings. The decisions could either limit or massively increase legal liabilities from the Monsanto acquisition, directly hitting the company’s profitability and survival outlook.
An unfavourable outcome could unleash a new wave of litigation costs, potentially eating into the company’s cash reserves and forcing asset sales or dividend cuts. The stock could drop another 20–40% as the market reprices the risk.
Yes—if both rulings significantly reduce liability or provide a path to settlement, the stock could rally sharply, recovering a portion of the $60 billion lost. Short-covering and improved sentiment could amplify the move.
Bayer shares collapsed by over $60 billion as investors price in outcomes of two decisive court rulings. The judgments will settle critical legal liabilities—mostly stemming from the Monsanto acquisition—that have dogged the German conglomerate for years. Market sentiment remains fragile ahead of the announcements.
The article points to two upcoming rulings that will decide key parts of Bayer’s legal exposure, most notably litigation related to its Monsanto unit, such as Roundup weedkiller cancer claims. The outcomes could either cap the liabilities or open the door to a flood of new claims.
The potential legal damages could run into tens of billions of dollars, severely straining Bayer’s balance sheet and future cash flow. The uncertainty has already erased over $60 billion in market cap, and the rulings will clarify the ultimate risk.